UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine
ISSN 2079-0325(p)
DOI 10.36927/2079-0325
Home » Archive of numbers » 2025 » Volume 33, issue 4 (125) » CLINICAL AND PHARMACOLOGICAL EVALUATION OF THE COMPATIBILITY OF METHADONE WITH DRUGS FOR PATIENTS WITH HIV INFECTION

CLINICAL AND PHARMACOLOGICAL EVALUATION OF THE COMPATIBILITY OF METHADONE WITH DRUGS FOR PATIENTS WITH HIV INFECTION

Authors

Type of Article

  • Scientific Article

In the Section

  • TO HELP A PRACTICING PHYSICIAN

Key words

Index UDK:
  • 615.214.32:615.03:616.98-085.281.8

Abstract

The aim of this study was to determine the clinical and pharmacological compatibility of methadone with antiretroviral drugs in HIV-infected patients receiving methadone maintenance therapy. A bibliosemantic and analytical evaluation was conducted using the certified databases DrugBank and HIV Drug Interactions, in combination with artificial intelligence technologies (GPT-5). It was established that tenofovir, lamivudine, and dolutegravir demonstrate high clinical compatibility with methadone and can be safely used in first-line treatment regimens. In contrast, efavirenz, nevirapine, ritonavir, atazanavir, and darunavir may decrease methadone concentrations or prolong the QT interval, requiring careful clinical supervision, ECG monitoring, and dose adjustment. The obtained results have practical significance for addiction specialists, infectious disease physicians, and clinical pharmacist, providing an evidence-based foundation for the safe pharmacotherapy of HIV infection in patients receiving methadone maintenance therapy.

Pages

  • 101-113

Year / Issue

Download PDF

References

  1. Degenhardt L, Webb P, Colledge Frisby S, et al. Epidemiology of injecting drug use, prevalence of injecting related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review. Lancet Glob Health. 2023;11(5):e659-e672. doi: https://doi.org/10.1016/S2214109X(23)000578
  2. Aghaei AM, Gholami J, Sangchooli A, et al. Prevalence of injecting drug use and HIV, hepatitis B and hepatitis C in people who inject drugs in the Eastern Mediterranean region: a systematic review and meta analysis. Lancet Glob Health. 2023;11(8):e1225-e1237. doi: https://doi.org/10.1016/S2214109X(23)00267X
  3. Korenromp EL, Rowley J, Valle A, et al. New HIV Infections Among Key Populations and Their Partners in 2010 and 2022, by World Region: A Multisources Estimation. J Acquir Immune Defic Syndr. 2024;95(1 Suppl):e34-e45.
  4. Pshenichnaya N, Paraskevis D, Shekhar K, et al. Prevalence and viral load suppression among people who inject drugs living with HIV in Ukraine: results from a national bio behavioural survey. PLoS One. 2023;18(8):e0290661. doi: https://doi.org/10.1371/journal.pone.0290661
  5. Smyrnov P, Williams LD, Korobchuk A, et al. Modeling the impact of opioid agonist therapy on HIV incidence among people who inject drugs in Ukraine. BMC Public Health. 2020;20:1459. doi: https://doi.org/10.1186/s12889020093732
  6. Yazdani K, Dolguikh K, Ye M, et al. Characterizing OAT uptake and factors associated with treatment retention among people with HIV in British Columbia, Canada. Prev Med Rep. 2023;35:102305. doi: https://doi.org/10.1016/j.pmedr.2023.102305
  7. Sever B, Otsuka M, Fujita M, Ciftci H. A Review of FDA Approved Anti HIV 1 Drugs, Anti Gag Compounds and Potential Strategies for HIV 1 Eradication. Int J Mol Sci. 2024;25(7):3659. doi: https://doi.org/10.3390/ijms25073659
  8. Azzman N, Gill MSA, Hassan SS, et al. Pharmacological advances in anti retroviral therapy for human immunodeficiency virus 1 infection: A comprehensive review. Rev Med Virol. 2024;34(2):e2529. doi: https://doi.org/10.1002/rmv.2529
  9. Zhao ACM, Cao WR, Geng RC. A clinical review of HIV integrase strand transfer inhibitors. Eur J  Clin Pharmacol. 2022;78(9):1377 1392. doi: https://doi.org/10.1007/s00228022 033147
  10. Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society– USA Panel. JAMA. 2023;329(1):63 doi: https://doi.org/10.1001/jama.2022.22246
  11. Brizzi M, Socías ME, Glick SN, et al. Rationale, evidence, and steps for implementation of integrated OUD and HIV care in safety net settings. Curr HIV/AIDS Rep. 2023;20(3):163-175. doi: https://doi.org/10.1007/s11904023006440
  12. Wyse JJ, Gordon KS, Edelman EJ, et al. Twelve month retention in opioid agonist treatment for OUD by HIV status. J Subst Abuse Treat. 2022;136:108672. doi: https://doi.org/10.1016/j.jsat.2021.108672
  13. Jaiswal J, Burrell E, Sen S, et al. Frontline staff perspectives on HIV and sex related, drug related stigma and PrEP implementation in methadone treatment settings. AIDS Behav. 2023;27(12):4029-4042. doi: https://doi.org/10.1007/s10461023041725
  14. McCance Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis. 2005;41(Suppl 1):S89- S95. doi: https://doi.org/10.1086/429503
  15. Міністерство охорони здоров’я України. Наказ № 916 від 03 червня 2025 р. “Про затвердження Стандарту медичної допомоги «ВІЛ інфекція»”. Київ; 2025. Ministerstvo okhorony zdorov’ia Ukrainy. Nakaz № 916 vid  03  chervnia 2025 r. Pro zatverdzhennia Standartu medychnoi dopomohy “VIL infektsiia” [Ministry of Health of Ukraine. Order No. 916 of June 3, 2025 On  Approval of the Standard of Medical Care “HIV Infection”]. Kyiv; 2025. https://moz.gov.ua/uk/decrees/nakaz-moz-ukrayini-vid-03-06-2025-916-pro-zatverdzhennyastandartu-medichnoyi-dopomogi-vil-infekciya.  (In Ukrainian).

Journal’s Indexing:

UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine

ДУ «ІНПН імені
П.В. ВОЛОШИНА
НАМН УКРАЇНИ»